郑州微飒生物科技有限责任公司 咨询热线:0371-88821766
行业动态

行业动态

追踪行业前沿,洞察产业趋势

药效评价Scale-down model qualification of ambr® 250 high-throughput mini-bioreactor system for two commercial-scale mAb processes.

期刊:Biotechnology progress发表年份:2019作者:Matthew Manahan; Michael Nelson; Jonathan J Cacciatore; Jessica Weng; Sen Xu; Jennifer Pollard

药效评价A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters.

期刊:Acta pharmacologica Sinica发表年份:2019作者:Mao-Xu Ge; Wei-Xiao Niu; Jin-Feng Ren; Shi-Ying Cai; Dong-Ke Yu; Hong-Tao Liu; Na Zhang; Yi-Xuan Zhang; Yu-Cheng Wang; Rong-Guang Shao; Ju-Xian Wang; Hong-Wei He

药效评价Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

期刊:mAbs发表年份:2019作者:Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer

药效评价Label-free impedance-based whole cell assay to study GPCR pharmacology.

期刊:Methods in cell biology发表年份:2019作者:Maarten L J Doornbos; Laura H Heitman